产品封面图
文献支持

A2780细胞

收藏
  • ¥1480
  • EK-Bioscience已认证
  • CCC-Y1557
  • 2026年01月08日
    avatar
    品牌商
    12钻石会员
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 规格

      T25

    【A2780】A2780细胞/A2780细胞/A2780人卵巢癌细胞Cell line name A2780

    Synonyms A-2780; 2780; A2780S; A2780par

    Accession CVCL_0134

    Resource Identification Initiative To cite this cell line use: A2780 (RRID:CVCL_0134)

    Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

    Part of: COSMIC cell lines project.

    Part of: KuDOS 95 cell line panel.

    Part of: MD Anderson Cell Lines Project.

    Part of: OCCP ovarian cancer cell line panel.

    Population: African American.

    Doubling time: 25.3 +- 1 hours (PubMed=3539322); 16 hours (PubMed=25984343); 18.41 hours (JWGray panel).

    Microsatellite instability: Instable (MSI-low) (PubMed=15677628; Sanger).

    Omics: Array-based CGH.

    Omics: CRISPR phenotypic screen.

    Omics: Deep exome analysis.

    Omics: Deep proteome analysis.

    Omics: Deep quantitative proteome analysis.

    Omics: DNA methylation analysis.

    Omics: Genome sequenced.

    Omics: GPI-anchored proteins analysis by proteomics.

    Omics: Metabolome analysis.

    Omics: N-glycan profiling by lectin array.

    Omics: Protein expression by reverse-phase protein arrays.

    Omics: Proteome analysis by 2D-DE/MS.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis by microarray.

    Omics: Transcriptome analysis by RNAseq.

    Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).

    Derived from site: In situ; Ovary; UBERON=UBERON_0000992.

    PubMed=23839242; DOI=10.1038/ncomms3126; PMCID=PMC3715866

    Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.

    Evaluating cell lines as tumour models by comparison of genomic profiles.

    Nat. Commun. 4:2126.1-2126.10(2013)

     

    PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837

    Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.

    Type-specific cell line models for type-specific ovarian cancer research.

    PLoS ONE 8:E72162-E72162(2013)

     

    PubMed=25230021; DOI=10.1371/journal.pone.0103988; PMCID=PMC4167545

    Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.

    Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

    PLoS ONE 9:E103988-E103988(2014)

     

    PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652

    Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

    Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

    Sci. Data 1:140035-140035(2014)

     

    PubMed=25485619; DOI=10.1038/nbt.3080

    Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

    A comprehensive transcriptional portrait of human cancer cell lines.

    Nat. Biotechnol. 33:306-312(2015)

     

    PubMed=25846456; DOI=10.3892/ijo.2015.2951

    Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M., Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.

    Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.

    Int. J. Oncol. 46:2389-2398(2015)

     

    PubMed=25877200; DOI=10.1038/nature14397

    Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

    A resource for cell line authentication, annotation and quality control.

    Nature 520:307-311(2015)

     

    PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

    Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

    TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

    Genome Med. 7:118.1-118.7(2015)

     

    PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008

    Masuishi Y., Kimura Y., Arakawa N., Hirano H.

    Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.

    J. Proteomics 139:77-83(2016)

     

    PubMed=27141528; DOI=10.1016/j.dib.2016.04.001; PMCID=PMC4838930

    Masuishi Y., Kimura Y., Arakawa N., Hirano H.

    Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.

    Data Brief 7:1302-1305(2016)

     

    PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028; PMCID=PMC4961516

    Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M.

    Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

    Gynecol. Oncol. 142:332-340(2016)

     

    PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

    Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., M T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

    A landscape of pharmacogenomic interactions in cancer.

    Cell 166:740-754(2016)

     

    PubMed=27561551; DOI=10.1038/ncomms12645; PMCID=PMC5007461

    Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.-Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.

    Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.

    Nat. Commun. 7:12645.1-12645.14(2016)

     

    PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

    Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

    Characterization of human cancer cell lines by reverse-phase protein arrays.

    Cancer Cell 31:225-239(2017)

     

    PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028

    Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.

    Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

    Cell Rep. 18:2343-2358(2017)

     

    PubMed=28546799; DOI=10.1186/s12014-017-9155-z; PMCID=PMC5442857

    Zhao R., Qin W.-J., Qin R.-H., Han J., Li C., Wang Y.-S., Xu C.-J.

    Lectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp.

    Clin. Proteomics 14:20.1-20.10(2017)

     

    PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945

    Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B.

    Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.

    Cell Rep. 25:2617-2633(2018)

     

    PubMed=30894224; DOI=10.1186/s40659-019-0220-0; PMCID=PMC6427839

    Viscarra T., Buchegger K., Jofre I.A., Riquelme I., Zanella L., Abanto Marin M., Parker A.C., Piccolo S.R., Roa J.C., Ili C.G., Brebi P.

    Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line.

    Biol. Res. 52:13.1-13.13(2019)

     

    PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

    Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

    An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

    Cancer Res. 79:1263-1273(2019)

     

    PubMed=30971826; DOI=10.1038/s41586-019-1103-9

    Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

    Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

    Nature 568:511-516(2019)

     

    PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

    Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

    Next-generation characterization of the Cancer Cell Line Encyclopedia.

    Nature 569:503-508(2019)

     

    PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254

    Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

    Quantitative proteomics of the Cancer Cell Line Encyclopedia.

    Cell 180:387-402.e16(2020)

     

    PubMed=33287223; DOI=10.3390/ijms21239218; PMCID=PMC7730278

    Szenajch J., Szabelska-Beresewicz A., Swiercz A., Zyprych-Walczak J., Siatkowski I., Goralski M., Synowiec A., Handschuh L.

    Transcriptome remodeling in gradual development of inverse resistance between paclitaxel and cisplatin in ovarian cancer cells.

    Int. J. Mol. Sci. 21:9218.1-9218.30(2020)

     

    PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775

    Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

    Pan-cancer proteomic map of 949 human cell lines.

    Cancer Cell 40:835-849.e8(2022)

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    *发表【中文论文】请标注:由上海酶研生物科技有限公司提供;

    *发表【英文论文】请标注:From Shanghai EK-Bioscience Biotechnology Co., Ltd.

    相关实验
    • 常用的细胞类型及其在细胞治疗中的应用

      细胞治疗是细胞和基因治疗的重要组成部分,它通过使用特定类型的细胞来修复、替换或调节受损的组织和器官。在细胞治疗中,不同类型的细胞因其独特的生物学特性而被广泛应用于多种疾病的治疗。以下是一些常用的细胞类型及其在细胞治疗中的应用。 (1)免疫细胞 免疫细胞细胞治疗中最重要且研究最多的细胞类型之一,主要包括 T 细胞、自然杀伤细胞(NK 细胞)和树突状细胞(DC 细胞)。 T 细胞:T 细胞是人体免疫系统的核心细胞,具有强大的抗肿瘤能力。CAR-T 细胞疗法是目前最成功的免疫细胞治疗技术

    • 轻松准确测定细胞增殖和细胞毒性

      简介 细胞增殖/细胞毒性测定是涉及培养细胞的研究中最常用的测试之一。 其是检查用于治疗的药物浓度的基本初步测试,也是确定各种研究领域(如肿瘤学和细胞死亡)药物疗效和安全性的非常重要的测试。   传统上,WST-8 或 ATP 检测(使用代谢活性作为指标)和 BrdU 或胸腺嘧啶核苷检测(使用 DNA 合成水平作为指标)已用于细胞生长特性的定量评估。 尽管这些检测由于其简易性和吞吐量而对我们有益,但这些检测都是间接评估方法,因此结果可能与实际细胞数无关。 在许多情况下,这些检测是终点评估,有时会

    • 细胞污染挽救

      对于贴壁生长的细胞,相对来说比较简单但也很麻烦。以下我主要讨论贴壁生长的细胞。 在讨论之前,大家首先要有一个概念,即洁净区,并不是没有细菌,而是细菌的数量非常少,国家标准100级的洁净标准是浮游菌数不得超过5个每立方米,沉降菌数不得超过1个每培养皿.而国外的标准比我国的还要高一点,要求的数量更少。 所以在我们的洁净操作台里,并不是真正一个细菌都没有的,所以在操作的时候还是要尽量利索迅速地完成操作。尽量减少进入培养体系细菌的数量。 所以处理细菌污染的重要原则就是:无限地稀释细菌的浓度,无限地减少

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥680
    上海联迈生物工程有限公司
    2025年09月11日询价
    ¥1320
    博辉生物科技(广州)有限公司
    2025年11月18日询价
    ¥800
    上海沪震实业有限公司
    2025年07月13日询价
    ¥800
    上海康朗生物科技有限公司
    2025年07月11日询价
    ¥2200
    上海钰博生物科技有限公司
    2024年04月07日询价
    文献支持
    A2780细胞
    ¥1480